SUPERNEWS - NYSE:LLY (Eli Lilly and Company) Stock Price, News, Quote, History

SUPERNEWS

Equities

Top Stories

Pre-Market: 3M and Eli Lilly Surge Pre-Fed, Chegg Stumbles

Eli Lilly Raises Forecast, Mounjaro & Zepbound Drive 7% Share Rise

Eli Lilly boosts revenue forecast by $2 billion due to soaring demand for Mounjaro and Zepbound, despite facing supply challenges.

4/30, 08:25 EDT

S&P 500 Breaks 5,100: Nvidia, Eli Lilly Overvalued?

Market Hits Record Highs, Sparks Valuation Concerns for Stocks like Nvidia and Eli Lilly; Opportunities in Amazon and Chewy Remain

2/28, 11:00 EST

Eli Lilly Earnings Uncertain Amid Drug Shortages, Up 25% YTD

Eli Lilly faces drug shortages impacting earnings, yet strong demand for obesity medication may bolster secondhalf revenue.

4/29, 13:39 EDT

Novo 30% Below Lilly Despite 350% Surge, Eyes Growth

Novo Nordisk's Wegovy faces supply challenges and pricing debates, trading at a 30% discount to Eli Lilly despite a 350% rally.

5/2, 09:35 EDT

Pre-Market: 3M and Eli Lilly Surge Pre-Fed, Chegg Stumbles

4/30, 07:58 EDT

Eli Lilly Raises Forecast, Mounjaro & Zepbound Drive 7% Share Rise

4/30, 08:25 EDT

S&P 500 Breaks 5,100: Nvidia, Eli Lilly Overvalued?

2/28, 11:00 EST

LLY News

Amgen Surges 12% on MariTide Hopes, Eyes Obesity Market

5/6, 09:07 EDT

Novo Down 5.3%, Amgen Up as Obesity Drug Race Heats Up

5/3, 05:44 EDT

Amgen Up 12% on MariTide, Targets $80B Market by 2030

5/2, 17:49 EDT

Novo 30% Below Lilly Despite 350% Surge, Eyes Growth

5/2, 09:35 EDT

Investors Demand More Than Just Earnings, Eye AI & Rates Impact

5/2, 04:55 EDT

ATI Grows 7% in Aerospace, Piedmont Eyes 126K dmt by 2024

5/1, 16:53 EDT

Pfizer Launches Direct Sales for Paxlovid, Targets Migraine Relief

5/1, 00:16 EDT

ATI Gains in Aerospace, Piedmont Ups Production, Buenaventura Profits

4/30, 17:18 EDT

Intraday: Earnings Season Shakes Wall Street: Winners and Losers Emerge

4/30, 14:16 EDT

Samsung Leads AI Boom, Eyes on AMD & Amazon for Future Demand

4/30, 11:33 EDT

Intraday: S&P 500 Dips Amid Mixed Corporate Fortunes, Fed Eyes

4/30, 10:40 EDT

Pre-Market: Labor Costs Worry Investors Ahead of Fed Meet, S&P Dips

4/30, 08:44 EDT

Eli Lilly Raises Forecast, Mounjaro & Zepbound Drive 7% Share Rise

4/30, 08:25 EDT

Pre-Market: 3M and Eli Lilly Surge Pre-Fed, Chegg Stumbles

4/30, 07:58 EDT

Eli Lilly Earnings Uncertain Amid Drug Shortages, Up 25% YTD

4/29, 13:39 EDT

Cox: Buy Health Stocks Now, Eyes on Novo & Novartis Growth

4/23, 12:21 EDT

Eli Lilly's Alzheimer's Drug to Outsell Rival, Hitting $5B by 2030

4/22, 06:25 EDT

Aspen Partners with Eli Lilly, Aims to Mitigate Drug Shortage

4/22, 02:24 EDT

Top 10 S&P 500 Stocks Overvalued: AI and Eli Lilly Lead

4/18, 15:19 EDT

Intraday: Mixed Market Moves: Boeing Dips, United Soars Amid Tech Struggles

4/17, 13:37 EDT

Nasdaq Falls 1.16%; Sage Therapeutics Dives 20%

4/17, 13:15 EDT

Intraday: UAL Soars 11%, ADSK Tumbles Amid Financial Probe

4/17, 10:34 EDT

Breakthrough Weight-loss Drug Shows Promise in Treating Sleep Apnea

4/17, 09:41 EDT

Rio Tinto Eyes 1M Tons Copper via Mines, Not Purchases

4/16, 16:51 EDT

BlackRock's Moore: Buy AI Stocks Amid Market Dip, Sees Upside

4/16, 11:53 EDT

Bear Put Strategy on AI Chips Aims for 100% ROI Amid Caution

4/16, 10:43 EDT

Nvidia Up 80%, Diversify with Emerson, Eli Lilly for Stability

4/16, 07:18 EDT

‘OMO’ Market Emerges Amid 3.6% S&P Growth, AI & Crypto Focus

4/12, 12:32 EDT

AstraZeneca CEO Gets £19M Amid Investor Split

4/11, 13:34 EDT

Cisco and Solar Stocks Shine, Restaurant Chains Wilt

4/9, 20:27 EDT

Wall Street Views

Barclays Plc

Emily Field, 5/3/24

Neutral on

AMGN

LLY

NVO

“As of today, we see no cause for concern regarding the competitive dynamics versus the market leaders... We really will need to see the data.”

Bloomberg Intelligence

Michael Shah, 5/2/24

Bullish on

AAPL

AMGN

EXPE

“Demand for anti-obesity drugs like Zepbound and Wegovy is so insatiable that Bloomberg Intelligence’s estimate for $80 billion in annual sales by 2030 is now looking conservative.”

JonesTrading

Michael O’Rourke, 5/2/24

Neutral on

LLY

NXPI

SPY

“A price-to-earnings ratio of over 20 had left the index 'nearly priced to perfection.' Therefore when a company disappoints, prices are likely to readjust sharply lower.”

RBC Capital Markets

Lori Calvasina, 5/2/24

Neutral on

LLY

NXPI

SPY

“I’m seeing an intolerance for the ‘we need to be patient’ conversation. The ‘wait and see, this is going to take time’ — investors don’t seem to have a lot of patience for that.”

University of California San Diego

Timothy Mackey, 5/1/24

Neutral on

LLY

PFE

“All it takes is one large company like Eli Lilly to do it and then more risk-averse companies follow suit... Pharma groups were realising that 'the best way to convert customers is through patient portals where they can act as a consumer in medicine.'”